Tag: Multiple Sclerosis
Generic Medications Can Keep OOP Costs Down for Neurological Conditions
Increase in out-of-pocket costs seen for multiple sclerosis medications per year by average of 217 percent
Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
Change in Modified Fatigue Impact Scale scores did not differ between the groups
Cancer Incidence Increased for People With Multiple Sclerosis
Small overall risk increase was mainly seen in women; higher risk seen for bladder, brain, cervical cancers
Aggressive, Early Disease-Modifying Therapy May Slow MS Progression
Development of paramagnetic rim lesions tied to more rapid disability progression
European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20
FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS
Phase 3 data show efficacy and safety profile similar to intravenous administration
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
Anti-CD20-treated primary progressive multiple sclerosis patients have higher risk for serious infection
Guidelines Provided for Diagnosis of Pediatric, Late-Onset Multiple Sclerosis
Unique biological features seen in children younger than 18 years, adults older than 50 years compared with typical adult-onset MS
Higher Burden of Comorbidity Linked to Worse Clinical Outcomes in MS
Presence of three or more comorbidities, two or more cardiometabolic comorbidities, one psychiatric disorder linked to evidence of disease activity
Multiple Sclerosis Linked to Lower Risk for Alzheimer Disease Pathology
Lower rate of amyloid-β plasma biomarker positivity seen in multiple sclerosis patients compared with non-MS controls
